Dr Hellmann presents results at AACR 2018 from CheckMate-227, assessing a combination of nivolumab and ipilimumab in cases of newly diagnosed non-small cell lung cancer with high mutational burden.

The 139 patients treated with the combination were 42% less likely to have their disease to progress compared to those treated with chemotherapy.

Overall survival data are still maturing.